ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease

Jeong Seok Lee1, Eun Young Lee2, Jin Kyun Park3, Eun Bong Lee2 and Yeong Wook Song4, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 3Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), 4Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Computed tomography (CT), Connective tissue diseases and interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Measuring severity of interstitial lung disease (ILD) usually depends on the extent or pattern of imaging findings on computed tomography (CT) and the parameters of pulmonary function test. Krebs von den Lungen 6 (KL-6) is a sialylated glycoprotein mainly expressed on the surface membrane of type II pneumocytes and bronchiolar epithelial cells (1). Serum level of KL-6 had been reported to be associated with presence or outcome of ILD associated with connective tissue diseases (CTD-ILD) (2-4). We aimed to evaluate KL-6 as a potential biomarker reflecting severity of CTD-ILD.

Methods: Study population was a retrospective cohort of 464 Korean patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), inflammatory myositis (IM), Sjogren¡¯s syndrome (SS), and systemic lupus erythematosus (SLE) who had concurrent ILD or not. Serum concentration of KL-6 (U/mL) was measured by Nanopia KL-6 assay (SEKISUI MEDICAL, Tokyo), using latex enhanced immunoturbidimetric assay method. Temporally nearest CT and PFT results were collected within 2 years from each serum sampling. Semi-quantitative grade of ILD extent (grade 1: 0-25%, grade 2: 26-50%, grade 3: 51-75%, grade 4: 76-100%) was evaluated by CT scan. Student t-test and Pearson¡¯s coefficient (PC) were applied to evaluate the correlation of KL-6 level and severity of ILD.

Results: The patients with CTD-ILD (n=162) had elevated serum level of KL-6 compared to CTD without ILD (n=302) (mean¡¾SEM, 737.9¡¾57.5 vs 238.2¡¾10.1U/mL, p<0.001) (Fig 1). In subgroup analysis, RA (544.6¡¾100.3 vs 241.7¡¾19.6, p<0.001), SSc (766.4¡¾103.7 vs 224.0¡¾26.3, p=0.002), IM (808.1¡¾99.8 vs 291.4¡¾33.1, p<0.001), and SS or SLE (914.1¡¾227.1 vs 215.0¡¾10.25, p<0.001) also had significant difference according to the presence of ILD. Semi-quantitative grade of ILD in CT scan was significantly proportional to KL-6 level except for grade 1 and 2 (Fig 2). Percent diffusion capacity for carbon monoxide (DLCO%) and forced vital capacity (FVC%) had negative correlation with KL-6 level (PC=-0.587, p<0.001; PC=-0.399, p<0.001, respectively).

Conclusion: Serum levels of KL-6 were increased in CTD-ILD and had good correlation with CT grade, FVC, and DLCO. Higher serum level of KL-6 may reflect severity of CTD-ILD.


Disclosure: J. S. Lee, None; E. Y. Lee, None; J. K. Park, None; E. B. Lee, Green Cross Corp, 2,Pfizer Inc, 5; Y. W. Song, CKD Research Institute, 2.

To cite this abstract in AMA style:

Lee JS, Lee EY, Park JK, Lee EB, Song YW. Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-kl-6-level-reflects-severity-of-interstitial-lung-disease-associated-with-connective-tissue-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-kl-6-level-reflects-severity-of-interstitial-lung-disease-associated-with-connective-tissue-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology